- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04590326
Estudio de REGN5668 administrado en combinación con Cemiplimab o REGN4018 en mujeres adultas con cáncer de ovario recurrente
Estudio de fase 1/2 de REGN5668 (MUC16xCD28, un biespecífico coestimulador) administrado en combinación con Cemiplimab o REGN4018 (MUC16xCD3)
This study is researching an investigational drug called REGN5668 :
- alone or,
- combined with cemiplimab (also known as REGN2810) or,
- combined with both cemiplimab and fianlimab (also known as REGN3767), or
- combined with ubamatamab (also known as REGN4018), with or without sarilumab.
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
- Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
- To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials Administrator
- Número de teléfono: 844-734-6643
- Correo electrónico: clinicaltrials@regeneron.com
Ubicaciones de estudio
-
-
-
São Paulo, Brasil, 01509-010
- Reclutamiento
- AC Camargo Cancer Center, Fundacao Antonio Prudente
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90619-900
- Reclutamiento
- Centro de Pesquisa em Oncologia PUCRS
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Reclutamiento
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
Sorocaba, São Paulo, Brasil, 18065-100
- Reclutamiento
- Unimed Sorocaba
-
-
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Bélgica, 3000
- Reclutamiento
- Universitair Ziekenhuis Leuven
-
-
-
-
-
Girona, España, 17007
- Reclutamiento
- Institut Catala dOncologia Girona
-
Madrid, España, 28040
- Reclutamiento
- Hospital Universitario Fundacion Jimenez
-
Madrid, España, 28040
- Reclutamiento
- Ciudad Universitaria
-
Madrid, España, 28041
- Reclutamiento
- Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
-
-
A Coruna
-
Santiago de Compostela, A Coruna, España, 15706
- Reclutamiento
- Hospital Clinico Universitario Santiago de Compostela
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Estados Unidos, 92618
- Reclutamiento
- The City of Hope Orange County Lennar Foundation Cancer Center
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- Chao Family Comprehensive Cancer Center
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Terminado
- H. Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-
Chicago, Illinois, Estados Unidos, 60637
- Reclutamiento
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Reclutamiento
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana Farber Cancer Institute Brookline Avenue
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Reclutamiento
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Perelman School of Medicine at the University of Pennsylvania
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Seattle Cancer Care Alliance at South Lake Union - G3630
-
-
-
-
-
Villejuif, Francia, 94805
- Reclutamiento
- Institut Gustave Roussy
-
-
Auvergne-Rhône
-
Pierre-Bénite, Auvergne-Rhône, Francia, 69310
- Reclutamiento
- Hopital Lyon Sud
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, Francia, 21000
- Reclutamiento
- Centre Georges Francois Leclerc
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Francia, 33076
- Reclutamiento
- Institut Bergonie
-
-
Normandy
-
Caen, Normandy, Francia, 14076
- Reclutamiento
- Centre Francois Baclesse (CFB)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
- Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
- Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
- Has adequate organ and bone marrow function as defined in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of at least 3 months
- Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol
Key Exclusion Criteria:
- Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
- Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
- Prior treatment with a Mucin 16 (MUC16)-targeted therapy
- Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
- Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Has history of clinically significant cardiovascular disease as defined in the protocol
- Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Module 1
REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab |
Administer per the protocol
Otros nombres:
Administer per the protocol
Otros nombres:
Administer per the protocol |
|
Experimental: Module 2
REGN5668 and ubamatamab |
Administer per the protocol
Otros nombres:
Administer per the protocol
Otros nombres:
Administer per the protocol
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLT)
Periodo de tiempo: 42 days
|
Dose escalation phase, Module 1 |
42 days
|
|
Incidence of DLTs
Periodo de tiempo: 21 days post combination administration
|
Dose escalation phase, Module 2 |
21 days post combination administration
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Periodo de tiempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of Serious Adverse Events (SAEs)
Periodo de tiempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of deaths
Periodo de tiempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Periodo de tiempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Periodo de tiempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase |
Through study completion, up to 5 years
|
|
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Periodo de tiempo: Through study completion, up to 5 years
|
Primary: Dose expansion phase |
Through study completion, up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
ORR based on RECIST 1.1
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation phase |
Through study completion, up to 5 years
|
|
Best Overall Response (BOR) based on RECIST 1.1
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Duration Of Response (DOR) based on RECIST 1.1
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Disease Control Rate (DCR) based on RECIST 1.1
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Progression-Free Survival (PFS) based on RECIST 1.1
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against REGN5668
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against ubamatamab
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against cemiplimab
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against fianlimab
Periodo de tiempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema endocrino
- Procesos Patológicos
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Atributos de la enfermedad
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias de glándulas endocrinas
- Enfermedades Ováricas
- Enfermedades anexiales
- Neoplasias Genitales Femeninas
- Trastornos gonadales
- Neoplasias Uterinas
- Enfermedades de las trompas de Falopio
- Condiciones Patológicas, Signos y Síntomas
- Reaparición
- Neoplasias Ováricas
- Neoplasias Endometriales
- Neoplasias de las trompas de Falopio
- cemiplimab
- sarilumab
Otros números de identificación del estudio
- R5668-ONC-1938
- 2022-501904-83-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Marco de tiempo para compartir IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criterios de acceso compartido de IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .